Plain-English translation of NCT06844422 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Read our Pancreatic Cancer research guide →Phase 1/2 — A combined trial that checks safety and dosing while also starting to look at whether the treatment works.
This study is testing a new drug called , which works by boosting your immune system to fight cancer while also cutting off the blood supply that tumors need to grow. You would receive this medication combined with focused radiation therapy (delivered over just two weeks) and chemotherapy infusions. The trial aims to find the safest and most effective dose of this new treatment when used alongside these other established cancer therapies.
Pancreatic cancer that cannot be removed with surgery is very difficult to treat, and current treatments don't work well enough for many patients. This medication is designed to attack cancer in two different ways at once, and researchers believe combining it with radiation and chemotherapy might help patients live longer without their cancer getting worse.
You likely qualify if…
You likely don't qualify if…
First, you would participate in an early phase where researchers test different doses of the medication to find the safest level—this takes about 4 weeks. Then, if the trial moves forward, you would receive the medication combined with focused radiation therapy given over two weeks, followed by 8 to 10 cycles of chemotherapy infusions (each cycle typically lasts about two weeks). After that, you would continue taking the medication alone for up to 12 months as maintenance treatment, with regular clinic visits to monitor how you're responding and watch for any side effects. Throughout the trial, you'll also provide blood and tissue samples for research.
AI-generated summary from trial data · Aug 11, 2026 · Not medical advice
China